$0.00
0.00% day before yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US2997341035
Symbol
EVLO
Sector
Industry

Evelo Biosciences, Inc. Stock price

$0.00
+0.00 0.00% 1M
-0.04 99.77% 6M
-0.06 99.84% YTD
-4.11 100.00% 1Y
-148.40 100.00% 3Y
-124.80 100.00% 5Y
-325.00 100.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.00 0.00%
ISIN
US2997341035
Symbol
EVLO
Sector
Industry

Key metrics

Market capitalization $0.00
Enterprise Value $16.69m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.00
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-73.84m
Free Cash Flow (TTM) Free Cash Flow $-73.99m
Cash position $17.26m
EPS (TTM) EPS $-13.35
Short interest 2.22%
Show more

Is Evelo Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Evelo Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evelo Biosciences, Inc.:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast Evelo Biosciences, Inc.:

Sell
100%

Financial data from Evelo Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
- -
-
100%
- Direct Costs 3.74 3.74
21% 21%
-
-3.74 -3.74
21% 21%
-
- Selling and Administrative Expenses 13 13
45% 45%
-
- Research and Development Expense 53 53
35% 35%
-
-70 -70
36% 36%
-
- Depreciation and Amortization 3.74 3.74
21% 21%
-
EBIT (Operating Income) EBIT -74 -74
36% 36%
-
Net Profit -82 -82
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Evelo Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evelo Biosciences, Inc. Stock News

Negative
Proactive Investors
12 months ago
Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding miss, the treatment failed to outperform the placebo, which has no therapeutic effect.
Negative
Market Watch
12 months ago
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 respons...
Neutral
GlobeNewsWire
12 months ago
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on t...
More Evelo Biosciences, Inc. News

Company Profile

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Craig Jalbert
Founded 2014
Website www.evelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today